Deltex Medical Group PLC Director Dealing (1372W)
July 30 2018 - 4:05AM
UK Regulatory
TIDMDEMG
RNS Number : 1372W
Deltex Medical Group PLC
30 July 2018
30 July 2018
Deltex Medical Group plc
("Deltex Medical" or the "Group")
Director Dealing
Deltex Medical Group plc (AIM: DEMG), the global leader in
Oesophageal Doppler Monitoring ("ODM"), was informed on Friday 27
July 2018 that Andy Mears, Chief Executive Officer of the Company,
purchased 2,234,222 ordinary shares of 1 pence each in the Company
("Ordinary Shares") at a price of 0.89 pence per Ordinary Share
during the day.
Following this transaction, Mr Mears' beneficial ownership is
2,781,808 Ordinary Shares, representing approximately 0.6 per cent.
of Deltex Medical's issued ordinary share capital.
For further information, please contact:-
Deltex Medical Group plc 01243 774 837
investorinfo@deltexmedical.com
Nigel Keen, Chairman
Andy Mears, Chief Executive
Jonathan Shaw, Group Finance
Director
Nominated Adviser & Broker
Arden Partners plc 020 7614 5900
Chris Hardie
Ciaran Walsh
Joint Broker
Turner Pope Investments (TPI) 0203 621 4120
Ltd info@turnerpope.com
Andy Thacker
Financial Public Relations
IFC Advisory 0203 934 6630
Tim Metcalfe
Graham Herring
Heather Armstrong
Notes for Editors
Deltex Medical manufactures and markets haemodynamic monitoring
technologies. Deltex Medical's proprietary ODM (TrueVue(TM)
Doppler) is the only technology to measure blood flow in the
central circulation in real time. Minimally invasive, easy to set
up and quick to focus, the technology generates a low-frequency
ultrasound signal, which is highly sensitive to changes in flow and
measures them immediately. Deltex has been the only group in the
enhanced haemodynamic space to build a robust and credible evidence
base proving the clinical and economic benefits of its core
technology, TrueVue(TM) Doppler, which is proven to reduce
complications suffered by patients after surgery and save hospitals
the costs of treating those complications.
Deltex Medical's TrueVue(TM) System on the CardioQ-ODM+ monitor
platform also now provides clinicians with two further advanced
haemodynamic monitoring technologies. High Definition Impedance
Cardiography (TrueVue(TM) Impedance) is an entirely non-invasive
monitoring technology which creates an electrical field across the
chest and measures the disruption to this field when the heart
pumps blood. Pulse Pressure Waveform Analysis
(TrueVue(TM) Pressurewave) uses peripheral blood pressure signal
analysis to give doctors information on changes in the circulation
and is particularly suited to monitoring lower risk or
haemodynamically stable patients.
Group goal
Haemodynamic management is now becoming widely accepted as an
important major new medical modality. Consequently, the Group's
focus is on maximising value from the opportunities presented, as
enhanced haemodynamic management is adopted into routine clinical
practice around the world. The Group aims to provide clinicians
with a single platform, a 'haemodynamic workstation', which offers
them a range of technologies from simple to sophisticated to be
deployed according to the patient's condition as well as the skill
and expertise of the user. Doing this will enable the Group to
partner healthcare providers to support modern haemodynamic
management across the whole hospital.
The Group is currently in the implementation phase of achieving
this goal in a number of territories worldwide, operating directly
in the UK, USA, Spain and Canada and through distribution
arrangements in a further 30 countries.
Note: This announcement contains inside information for the
purposes of Article 7 of Regulation (EU) No 596/2014.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities ("PDMRs") and persons
closely associated with them.
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Names Andy Mears - Chief Executive Officer
------------------------- -------------------------------------------
2 Reason for the notification
----------------------------------------------------------------------
a) Position/status See 1(a) above for position - classified
as a PDMR of Deltex Medical
------------------------- -------------------------------------------
b) Initial notification Initial
/Amendment
------------------------- -------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------
a) Name Deltex Medial Group plc
------------------------- -------------------------------------------
b) LEI 213800XN34P6LI8J6M39
------------------------- -------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
----------------------------------------------------------------------
a) Description of Ordinary shares of 1 pence each ("Ordinary
the financial Shares")
instrument, type
of instrument
------------------------- -------------------------------------------
b) Identification GB0059337583
code
------------------------- -------------------------------------------
c) Nature of the Purchase of Ordinary Shares
transaction
------------------------- -------------------------------------------
d) Price(s) and volume(s) Prices(s) Volume(s)
0.89 pence 2,234,222
----------
------------------------- -------------------------------------------
d) Aggregated information N/a
- Aggregated volume
- Price
------------------------- -------------------------------------------
e) Date of the transaction 27 July 2018
------------------------- -------------------------------------------
f) Place of the transaction London Stock Exchange, AIM Market (XLON)
------------------------- -------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHLIFITDFIIVIT
(END) Dow Jones Newswires
July 30, 2018 04:05 ET (08:05 GMT)
Deltex Medical (LSE:DEMG)
Historical Stock Chart
From Apr 2024 to May 2024
Deltex Medical (LSE:DEMG)
Historical Stock Chart
From May 2023 to May 2024